Live Breaking News & Updates on Paul Edward Walker

Stay updated with breaking news from Paul edward walker. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Genocea Biosciences, Inc. (NASDAQ:GNCA) Short Interest Up 118.9% in May

Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) saw a significant increase in short interest in May. As of May 31st, there was short interest totalling 3,590,000 shares, an increase of 118.9% from the May 15th total of 1,640,000 shares. Currently, 13.6% of the company’s stock are short sold. Based on an average daily volume of […] ....

Stifel Nicolaus , Genocea Biosciences , Robertw Baird , Paul Edward Walker , Ali Behbahani , Morgan Stanley , Northern Trust Corp , Geode Capital Management , Renaissance Technologies , Millennium Management , Genocea Biosciences Inc , Get Rating , Director Ali Behbahani , Capital Management , Trust Corp , Nasdaq Gnca ,

Genocea Biosciences, Inc. (NASDAQ:GNCA) Sees Large Growth in Short Interest

Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) was the recipient of a significant growth in short interest in May. As of May 31st, there was short interest totalling 3,590,000 shares, a growth of 118.9% from the May 15th total of 1,640,000 shares. Currently, 13.6% of the company’s stock are sold short. Based on an average […] ....

Stifel Nicolaus , Genocea Biosciences , Robertw Baird , Paul Edward Walker , Ali Behbahani , Morgan Stanley , Northern Trust Corp , Securities Exchange Commission , Renaissance Technologies , Commonwealth Equity Services , Genocea Biosciences Inc , Acadian Asset Management , Genocea Biosciences Company Profile Get Rating , Get Rating , Exchange Commission , Director Ali Behbahani , Asset Management , Equity Services , Trust Corp , Biosciences Company Profile , Nasdaq Gnca ,

Trevi Therapeutics (NASDAQ:TRVI) Now Covered by Analysts at Oppenheimer

Investment analysts at Oppenheimer started coverage on shares of Trevi Therapeutics (NASDAQ:TRVI – Get Rating) in a note issued to investors on Tuesday, The Fly reports. The brokerage set an “outperform” rating on the stock. A number of other equities research analysts have also commented on TRVI. Aegis began coverage on Trevi Therapeutics in a […] ....

Paul Edward Walker , Securities Exchange Commission , Zacks Investment Research , Renaissance Technologies , Wealthtrust Axiom , Millennium Management , Vanguard Group Inc , Trevi Therapeutics Inc , Trevi Therapeutics , Get Rating , Investment Research , Exchange Commission , Trust Axiom , Nasdaq Trvi , Initiated Coverage , Oppenheimer Holdings Inc ,

Metacrine, Inc. (NASDAQ:MTCR) Short Interest Update

Metacrine, Inc. (NASDAQ:MTCR – Get Rating) was the recipient of a large decrease in short interest in February. As of February 28th, there was short interest totalling 465,600 shares, a decrease of 20.9% from the February 13th total of 588,600 shares. Based on an average daily volume of 3,470,000 shares, the short-interest ratio is presently […] ....

Paul Edward Walker , Morgan Stanley , Securities Exchange Commission , Goldman Sachs Group Inc , Metacrine Company Profile Get Rating , Virtu Financial , Zacks Investment Research , Walleye Capital , Citadel Advisors , Metacrine Inc , Get Rating , Exchange Commission , Goldman Sachs Group , Sachs Group , Company Profile , Nasdaq Mtcr ,